2024-04-15 16:35:18 ET
Summary
- Candel Therapeutics, Inc. released positive interim results from the phase 2 study using CAN-2409 for treatment of patients with pancreatic ductal adenocarcinoma; Patients that took the drug with SOC achieved mOS of 28.8 months.
- Orphan Drug Designation is given by FDA for CAN-2409 for the treatment of patients with borderline respectable pancreatic ductal adenocarcinoma.
- Results from phase 2 study using CAN-2409 for the treatment of patients with non-small cell lung cancer, expected Q2 of 2024.
- Data readouts from two other studies expected in Q4 of 2024, both of which deal with the targeting of patients with localized prostate cancer using CAN-2409.
Candel Therapeutics, Inc. ( CADL ) was able to report positive interim results from its phase 2 randomized study using CAN-2409 plus valacyclovir [prodrug] together with standard of care [SOC] chemoradiation, following by resection in patients with borderline respectable pancreatic ductal adenocarcinoma [PDAC]. Not only that, but it also achieved Orphan Drug Designation [ODD] of CAN-2409 for the treatment of this patient population....
Read the full article on Seeking Alpha
For further details see:
Candel Therapeutics: CAN-2409 May Go Beyond Scope Of Targeting Pancreatic Cancer